JP2025511161A - Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ - Google Patents

Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ Download PDF

Info

Publication number
JP2025511161A
JP2025511161A JP2024557983A JP2024557983A JP2025511161A JP 2025511161 A JP2025511161 A JP 2025511161A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2025511161 A JP2025511161 A JP 2025511161A
Authority
JP
Japan
Prior art keywords
group
groups
substituted
unsubstituted
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511161A5 (https=
JPWO2023194310A5 (https=
Inventor
ジョン－クリストフ・ル・バイユ
ユルゲン・モル
サルヴィナ・タムマッカロ
イリス・ヴァルティンゴジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2025511161A publication Critical patent/JP2025511161A/ja
Publication of JP2025511161A5 publication Critical patent/JP2025511161A5/ja
Publication of JPWO2023194310A5 publication Critical patent/JPWO2023194310A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024557983A 2022-04-04 2023-04-03 Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ Pending JP2025511161A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305439 2022-04-04
EP22305439.6 2022-04-04
PCT/EP2023/058693 WO2023194310A1 (en) 2022-04-04 2023-04-03 Therapeutic combination of kras g12c inhibitor and tead inhibitor

Publications (3)

Publication Number Publication Date
JP2025511161A true JP2025511161A (ja) 2025-04-15
JP2025511161A5 JP2025511161A5 (https=) 2026-04-10
JPWO2023194310A5 JPWO2023194310A5 (https=) 2026-04-10

Family

ID=81326107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557983A Pending JP2025511161A (ja) 2022-04-04 2023-04-03 Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ

Country Status (5)

Country Link
US (1) US20250295664A1 (https=)
EP (1) EP4504203A1 (https=)
JP (1) JP2025511161A (https=)
CN (1) CN118973584A (https=)
WO (1) WO2023194310A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020055761A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
TW202128699A (zh) * 2019-11-27 2021-08-01 美商建南德克公司 治療性化合物
US20230140808A1 (en) 2020-04-07 2023-05-04 Sanofi (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP7774612B2 (ja) 2020-07-30 2025-11-21 サノフイ アクリルアミド置換インダン化合物およびその治療的使用

Also Published As

Publication number Publication date
EP4504203A1 (en) 2025-02-12
CN118973584A (zh) 2024-11-15
WO2023194310A1 (en) 2023-10-12
US20250295664A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
JP5997763B2 (ja) タンパク質キナーゼ阻害剤としての大環状化合物
US9284298B2 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
JP2022534426A (ja) Ｔｅａｄ阻害剤およびその使用
US9333205B2 (en) Isoxazolo-quinazolines as modulators of protein kinase activity
US20150342945A1 (en) Substituted quinoline compounds and methods of use
CN117447479B (zh) 一种靶向肿瘤免疫激酶的吡咯并吡嗪衍生物、制备方法及其应用
EP3233840A1 (en) Heterocyclic derivatives modulating activity of certain protein kinases
WO2012101032A1 (en) Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
JP2023533464A (ja) がんを治療するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＫＲＡＳ阻害剤の組合せ
JP2025511161A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
TW202313050A (zh) 組合療法
JP2023532675A (ja) ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ
WO2016115869A1 (zh) Flt3激酶的新型抑制剂及其用途
JP2015510945A (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
CN114206869A (zh) Cxcr4抑制剂和其用途
CN117447470B (zh) 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
US20250042918A1 (en) Compounds
HK40105285A (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402